{"title":"细胞减少手术加腹腔内高温化疗可提高ii期卵巢癌患者的生存率","authors":"LU Yula","doi":"10.14188/J.1671-8852.2015.04.015","DOIUrl":null,"url":null,"abstract":"Objective:To evaluate the clinical efficacy and perioperative safety of cytoreductive surgery(CRS)in conjunction with hyperthermic intraperitonealchemotherapy(HIPEC)for treating patients with stage Ⅲc ovarian cancer.Methods:A total of 50 stage Ⅲc ovarian cancer patients were divided into the CRS(n=30),and the CRS + HIPEC group(n=24).The primary end point was overall survival(OS)and the second end points were serious adverse events(SAE).Results:The median follow-up was 44.1 months(6to 168 months)in CRS Group and 42.6months(10.5to 110.9 months)in CRS + HIPEC Group.The median OS was 27.1 months(95%CI,21.8-35.3 months)in CRS Group and 32.6 months(95%CI,24.8-40.6 months)in CRS + HIPEC Group(P0.05).Within 30 days after the surgery,SAE occurred in 3of the 30 patients in CRS Group,and in 5of the 24 patients in CRS+HIPEC Group(P=0.466).Multivariate analysis revealed that CRS + HIPEC,operation satisfaction,and chemotherapy over sixcycles were the independent factors for OS improvement.Conclusion:The CRS+HIPEC method improves the OS of stageⅢ c ovarian cancer patients,suggesting an acceptable safety.","PeriodicalId":35402,"journal":{"name":"武汉大学学报(医学版)","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survivalin Patients with StageIIIc Ovarian Cancer\",\"authors\":\"LU Yula\",\"doi\":\"10.14188/J.1671-8852.2015.04.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective:To evaluate the clinical efficacy and perioperative safety of cytoreductive surgery(CRS)in conjunction with hyperthermic intraperitonealchemotherapy(HIPEC)for treating patients with stage Ⅲc ovarian cancer.Methods:A total of 50 stage Ⅲc ovarian cancer patients were divided into the CRS(n=30),and the CRS + HIPEC group(n=24).The primary end point was overall survival(OS)and the second end points were serious adverse events(SAE).Results:The median follow-up was 44.1 months(6to 168 months)in CRS Group and 42.6months(10.5to 110.9 months)in CRS + HIPEC Group.The median OS was 27.1 months(95%CI,21.8-35.3 months)in CRS Group and 32.6 months(95%CI,24.8-40.6 months)in CRS + HIPEC Group(P0.05).Within 30 days after the surgery,SAE occurred in 3of the 30 patients in CRS Group,and in 5of the 24 patients in CRS+HIPEC Group(P=0.466).Multivariate analysis revealed that CRS + HIPEC,operation satisfaction,and chemotherapy over sixcycles were the independent factors for OS improvement.Conclusion:The CRS+HIPEC method improves the OS of stageⅢ c ovarian cancer patients,suggesting an acceptable safety.\",\"PeriodicalId\":35402,\"journal\":{\"name\":\"武汉大学学报(医学版)\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"武汉大学学报(医学版)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14188/J.1671-8852.2015.04.015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"武汉大学学报(医学版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14188/J.1671-8852.2015.04.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survivalin Patients with StageIIIc Ovarian Cancer
Objective:To evaluate the clinical efficacy and perioperative safety of cytoreductive surgery(CRS)in conjunction with hyperthermic intraperitonealchemotherapy(HIPEC)for treating patients with stage Ⅲc ovarian cancer.Methods:A total of 50 stage Ⅲc ovarian cancer patients were divided into the CRS(n=30),and the CRS + HIPEC group(n=24).The primary end point was overall survival(OS)and the second end points were serious adverse events(SAE).Results:The median follow-up was 44.1 months(6to 168 months)in CRS Group and 42.6months(10.5to 110.9 months)in CRS + HIPEC Group.The median OS was 27.1 months(95%CI,21.8-35.3 months)in CRS Group and 32.6 months(95%CI,24.8-40.6 months)in CRS + HIPEC Group(P0.05).Within 30 days after the surgery,SAE occurred in 3of the 30 patients in CRS Group,and in 5of the 24 patients in CRS+HIPEC Group(P=0.466).Multivariate analysis revealed that CRS + HIPEC,operation satisfaction,and chemotherapy over sixcycles were the independent factors for OS improvement.Conclusion:The CRS+HIPEC method improves the OS of stageⅢ c ovarian cancer patients,suggesting an acceptable safety.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
